US 12,329,801 B2
Regenerative polypeptides and uses thereof
Hanadie Yousef, Palo Alto, CA (US); Jeremy O'Connell, Palo Alto, CA (US); Thach Mai, South San Francisco, CA (US); and Zhihua Li, San Jose, CA (US)
Assigned to JUVENA THERAPEUTICS, INC., Redwood City, CA (US)
Filed by JUVENA THERAPEUTICS, INC., Redwood City, CA (US)
Filed on May 13, 2024, as Appl. No. 18/662,443.
Application 18/662,443 is a continuation of application No. 18/572,740, previously published as PCT/US2022/033059, filed on Jun. 10, 2022.
Claims priority of provisional application 63/259,088, filed on Jun. 21, 2021.
Prior Publication US 2024/0294597 A1, Sep. 5, 2024
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 38/30 (2006.01); A61P 21/00 (2006.01); C07K 14/65 (2006.01); C07K 14/765 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 9/0019 (2013.01); A61K 38/30 (2013.01); A61P 21/00 (2018.01); C07K 14/65 (2013.01); C07K 14/765 (2013.01); C07K 2319/31 (2013.01)] 12 Claims
 
1. A fusion protein comprising an insulin-like growth factor 2 (IGF2) polypeptide fused to an N-terminal human serum albumin (HSA) polypeptide, wherein the IGF2 polypeptide comprises the amino acid sequence of SEQ ID NO: 29 and an R61A mutation in the amino acid sequence of SEQ ID NO: 32, wherein the R61A mutation resides within an IGF2 C-domain, and wherein the fusion protein exhibits reduced cleavage within the IGF2 C-domain.